Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.

Gao JH, Chu XC, Wang LL, Ning B, Zhao CX.

Medicine (Baltimore). 2017 Oct;96(40):e8059. doi: 10.1097/MD.0000000000008059.

2.

Decreased Rivaroxaban Levels in a Patient with Cerebral Vein Thrombosis Receiving Phenytoin.

Becerra AF, Amuchastegui T, Tabares AH.

Case Rep Hematol. 2017;2017:4760612. doi: 10.1155/2017/4760612. Epub 2017 Aug 10.

3.

Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty.

Hur M, Park SK, Koo CH, Jung ED, Kang P, Kim WH, Kim JT, Jung CW, Bahk JH.

Acta Orthop. 2017 Dec;88(6):634-641. doi: 10.1080/17453674.2017.1361131. Epub 2017 Aug 8. Review.

4.

Rivaroxaban: An Affordable and Effective Alternative in Cancer-Related Thrombosis?

Xavier FD, Hoff PMG, Braghiroli MI, Paterlini ACCR, Souza KT, Faria LDBB, Ferreira FSB, Machado KK, Fernandes GDS.

J Glob Oncol. 2016 Jun 22;3(1):15-22. doi: 10.1200/JGO.2015.002527. eCollection 2017 Feb.

5.

Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.

Boyd RA, DiCarlo L, Mandema JW.

Clin Transl Sci. 2017 Jul;10(4):260-270. doi: 10.1111/cts.12471. Epub 2017 May 23.

7.

Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.

Yan X, Gu X, Xu Z, Lin H, Wu B.

Adv Ther. 2017 Feb;34(2):466-480. doi: 10.1007/s12325-016-0460-0. Epub 2016 Dec 20.

8.

Quantitative Systems Pharmacology Model to Predict the Effects of Commonly Used Anticoagulants on the Human Coagulation Network.

Hartmann S, Biliouris K, Lesko LJ, Nowak-Göttl U, Trame MN.

CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):554-564. doi: 10.1002/psp4.12111. Epub 2016 Sep 20.

9.

Efficacy and safety of rivaroxaban thromboprophylaxis after arthroplasty of the hip or knee: retrospective cohort study.

Loganathan L, Hua A, Patel S, Gibbons C, Vizcaychipi MP.

Ann R Coll Surg Engl. 2016 Sep;98(7):507-15. doi: 10.1308/rcsann.2016.0197.

10.

Caprini Scores, Risk Stratification, and Rivaroxaban in Plastic Surgery: Time to Reconsider Our Strategy.

Swanson E.

Plast Reconstr Surg Glob Open. 2016 Jun 13;4(6):e733. doi: 10.1097/GOX.0000000000000660. eCollection 2016 Jun.

12.

Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.

Ning GZ, Kan SL, Chen LX, Shangguan L, Feng SQ, Zhou Y.

Sci Rep. 2016 Mar 29;6:23726. doi: 10.1038/srep23726.

13.

Enoxaparin and rivaroxaban have different effects on human mesenchymal stromal cells in the early stages of bone healing.

Pilge H, Fröbel J, Prodinger PM, Mrotzek SJ, Fischer JC, Zilkens C, Bittersohl B, Krauspe R.

Bone Joint Res. 2016 Mar;5(3):95-100. doi: 10.1302/2046-3758.53.2000595.

14.

Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: an in-vitro study comparing enoxaparin with rivaroxaban.

Pilge H, Fröbel J, Mrotzek SJ, Fischer JC, Prodinger PM, Zilkens C, Bittersohl B, Krauspe R.

BMC Musculoskelet Disord. 2016 Mar 1;17:108. doi: 10.1186/s12891-016-0966-2.

15.

Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.

Martinelli I, Lensing AW, Middeldorp S, Levi M, Beyer-Westendorf J, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Trajanovic M, Gebel M, Lam P, Wells PS, Prins MH.

Blood. 2016 Mar 17;127(11):1417-25. doi: 10.1182/blood-2015-08-665927. Epub 2015 Dec 22.

16.

Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program.

Yamada N, Hirayama A, Maeda H, Sakagami S, Shikata H, Prins MH, Lensing AW, Kato M, Onuma J, Miyamoto Y, Iekushi K, Kajikawa M.

Thromb J. 2015 Jan 17;13:2. doi: 10.1186/s12959-015-0035-3. eCollection 2015. Erratum in: Thromb J. 2016;14:11.

17.

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy.

Wells PS, Gebel M, Prins MH, Davidson BL, Lensing AW.

Thromb J. 2014 Nov 26;12:26. doi: 10.1186/1477-9560-12-26. eCollection 2014.

18.

Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.

Prandoni P, Prins MH, Cohen AT, Müller K, Pap ÁF, Tewes MC, Lensing AW.

Acad Emerg Med. 2015 Feb;22(2):142-9. doi: 10.1111/acem.12585. Epub 2015 Feb 9.

19.

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.

Ageno W, Mantovani LG, Haas S, Kreutz R, Haupt V, Schneider J, Turpie AG.

Thromb J. 2014 Jul 14;12:16. doi: 10.1186/1477-9560-12-16. eCollection 2014.

20.

New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty.

Aikens GB, Osmundson JR, Rivey MP.

World J Orthop. 2014 Jul 18;5(3):188-203. doi: 10.5312/wjo.v5.i3.188. eCollection 2014 Jul 18. Review.

Supplemental Content

Loading ...
Support Center